{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:45:41Z","timestamp":1789062341226,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Most men undergoing androgen deprivation therapy (ADT) for prostate cancer experience hot flushes. Current treatments have low or limited evidence of efficacy. It is likely that oestradiol depletion is the mediator of these hot flushes, and transdermal oestradiol might be an effective treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>This is a 6-month randomised, placebo-controlled trial with the hypothesis that oestradiol would reduce hot flush frequency and intensity and improve quality of life (QoL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Seventy-eight participants receiving ADT were randomised to 0.9 mg of 0.1% oestradiol gel per day or matched placebo. Hot flush frequency and severity were assessed by 7-day diary at baseline, month 1, month 3, and month 6. QoL was assessed by validated questionnaire.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Oestradiol reduced daily hot flush frequency, with a mean adjusted difference (MAD) of \u22121.6 hot flushes per day (95% CI: \u22122.7 to \u22120.5; P = 0.04). The effect on weekly hot flush score was non-significant, with a MAD \u201319.6 (95% CI: \u221235.5 to \u22123.8; P = 0.11). On per protocol analysis, E2 significantly reduced daily hot flush frequency, with a MAD of \u22122.2 hot flushes per day (95% CI: \u22123.2 to \u22121.1; P = 0.001), and weekly hot flush score, with a MAD of \u221227.0 (\u221244.7 to \u22129.3; P = 0.02). Oestradiol had no significant effect on QoL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We confirmed our hypothesis of a clinical effect of assignment to oestradiol to reduce hot flush frequency in men with castrate testosterone due to ADT. Transdermal oestradiol could be considered for men with burdensome hot flushes in whom other treatments have failed as long as the risk of breast effects and fat gain are considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1530\/eje-22-0318","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T08:38:41Z","timestamp":1662453521000},"page":"617-627","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":12,"title":["Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-6601","authenticated-orcid":false,"given":"Nicholas","family":"Russell","sequence":"first","affiliation":[{"name":"Department of Medicine (Austin Health), The University of Melbourne , Heidelberg, Australia"},{"name":"Department of Endocrinology, Austin Health , Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-4270","authenticated-orcid":false,"given":"Rudolf","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health), The University of Melbourne , Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-5525","authenticated-orcid":false,"given":"Ada S","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health), The University of Melbourne , Heidelberg, Australia"},{"name":"Department of Endocrinology, Austin Health , Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Zajac","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health), The University of Melbourne , Heidelberg, Australia"},{"name":"Department of Endocrinology, Austin Health , Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-3457","authenticated-orcid":false,"given":"Mathis","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health), The University of Melbourne , Heidelberg, Australia"},{"name":"Department of Endocrinology, Austin Health , Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"2023010809172777200_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5694\/j.1326-5377.2011.tb02979.x","article-title":"Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy","volume":"194","author":"Grossmann","year":"2011","journal-title":"Medical Journal of Australia"},{"key":"2023010809172777200_bib2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"European Urology"},{"key":"2023010809172777200_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"European Urology"},{"key":"2023010809172777200_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/cen.13249","article-title":"Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy","volume":"86","author":"Cheung","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"2023010809172777200_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","article-title":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy","volume":"11","author":"Nishiyama","year":"2004","journal-title":"International Journal of Urology"},{"key":"2023010809172777200_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma","volume":"152","author":"Karling","year":"1994","journal-title":"Journal of Urology"},{"key":"2023010809172777200_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cncr.31024","article-title":"Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: the role of hot flashes and nocturia","volume":"124","author":"Gonzalez","year":"2018","journal-title":"Cancer"},{"key":"2023010809172777200_bib8","first-page":"E86","article-title":"Comparing interventions for management of hot flashes in patients with breast and prostate cancer: a systematic review with meta-analyses","volume":"47","author":"Hutton","year":"2020","journal-title":"Oncology Nursing Forum"},{"key":"2023010809172777200_bib9","author":"National Institute for Health and Care Excellence","year":"2019","journal-title":"Prostate cancer: diagnosis and management"},{"key":"2023010809172777200_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1188\/20.ONF.374-399","article-title":"ONS GuidelinesTM for cancer treatment-related hot flashes in women with breast cancer and men with prostate cancer","volume":"47","author":"Kaplan","year":"2020","journal-title":"Oncology Nursing Forum"},{"key":"2023010809172777200_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet: Oncology"},{"key":"2023010809172777200_bib12","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/srep08466","article-title":"Neurokinin B administration induces hot flushes in women","volume":"5","author":"Jayasena","year":"2015","journal-title":"Scientific Reports"},{"key":"2023010809172777200_bib13","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809172777200_bib14","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/01.AOG.0000254160.62588.41","article-title":"Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial","volume":"109","author":"Simon","year":"2007","journal-title":"Obstetrics and Gynecology"},{"key":"2023010809172777200_bib15","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1210\/jc.2016-1612","article-title":"Effects of testosterone and estradiol deficiency on vasomotor symptoms in hypogonadal men","volume":"101","author":"Taylor","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809172777200_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1530\/EJE-17-1072","article-title":"Short-term effects of transdermal estradiol in men undergoing androgen deprivation therapy for prostate cancer: a randomized placebo-controlled trial","volume":"178","author":"Russell","year":"2018","journal-title":"European Journal of Endocrinology"},{"key":"2023010809172777200_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1530\/EJE-21-0663","article-title":"Effects of estradiol on fat in men undergoing androgen deprivation therapy: a randomized trial","volume":"186","author":"Russell","year":"2021","journal-title":"European Journal of Endocrinology"},{"key":"2023010809172777200_bib18","author":"Russell","year":"2014","journal-title":"Biological actions of estradiol in men trial: registration on the Australian and New Zealand Clinical Trials Registry"},{"key":"2023010809172777200_bib19","volume-title":"CONSORT Checklist: Effects of Estradiol Treatment on Hot Flushes and Quality of Life in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial","author":"Russell","year":"2022"},{"key":"2023010809172777200_bib20","author":"NIH National Cancer Institute","year":"2010","journal-title":"Common terminology criteria for adverse events version 4.03"},{"key":"2023010809172777200_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"2023010809172777200_bib22","first-page":"155","article-title":"A qualitative approach to defining \u2018hot flashes\u2019 in men","volume":"14","author":"Quella","year":"1994","journal-title":"Urologic Nursing"},{"key":"2023010809172777200_bib23","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"2023010809172777200_bib24","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","article-title":"Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument","volume":"50","author":"Esper","year":"1997","journal-title":"Urology"},{"key":"2023010809172777200_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/tam.4.1.14.22","article-title":"The aging males' symptoms rating scale: cultural and linguistic validation into English","volume":"4","author":"Heinemann","year":"2001","journal-title":"Aging Male"},{"key":"2023010809172777200_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.eururo.2004.01.009","article-title":"The aging males' symptoms scale (AMS) as outcome measure for treatment of androgen deficiency","volume":"46","author":"Moore","year":"2004","journal-title":"European Urology"},{"key":"2023010809172777200_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cca.2009.09.003","article-title":"Development and validation of a sensitive liquid chromatography\u2013tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization","volume":"409","author":"Harwood","year":"2009","journal-title":"Clinica Chimica Acta"},{"key":"2023010809172777200_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"Journal of Statistical Software"},{"key":"2023010809172777200_bib29","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"2023010809172777200_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v087.i09","article-title":"Visualizing fit and lack of fit in complex regression models with predictor effect plots and partial residuals","volume":"87","author":"Fox","year":"2018","journal-title":"Journal of Statistical Software"},{"key":"2023010809172777200_bib31","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised prostate adenocarcinoma transcutaneous hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"2023010809172777200_bib32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bju.13687","article-title":"Quality-of-life outcomes from the prostate adenocarcinoma: transcutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer","volume":"119","author":"Gilbert","year":"2017","journal-title":"BJU International"},{"key":"2023010809172777200_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euros.2021.04.005","article-title":"Estetrol cotreatment of androgen deprivation therapy in infiltrating or metastatic, castration-sensitive prostate cancer: a randomized, double-blind, phase II trial (PCombi)","volume":"28","author":"Bennink","year":"2021","journal-title":"European Urology Open Science"},{"key":"2023010809172777200_bib34","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1002\/jps.23600","article-title":"Investigation of the effect of active efflux at the blood\u2013brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system","volume":"102","author":"Miyajima","year":"2013","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"2023010809172777200_bib35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1530\/EJE-15-0380","article-title":"Age-specific population centiles for androgen status in men","volume":"173","author":"Handelsman","year":"2015","journal-title":"European Journal of Endocrinology"},{"key":"2023010809172777200_bib36","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-18-1000","article-title":"MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone","volume":"181","author":"Russell","year":"2019","journal-title":"European Journal of Endocrinology"},{"key":"2023010809172777200_bib37","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdn644","article-title":"A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)","volume":"20","author":"Loprinzi","year":"2009","journal-title":"Annals of Oncology"},{"key":"2023010809172777200_bib38","doi-asserted-by":"crossref","first-page":"R297","DOI":"10.1530\/ERC-17-0153","article-title":"Estradiol for the mitigation of adverse effects of androgen deprivation therapy","volume":"24","author":"Russell","year":"2017","journal-title":"Endocrine-Related Cancer"},{"key":"2023010809172777200_bib39","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00520-019-05255-5","article-title":"Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review","volume":"28","author":"Edmunds","year":"2020","journal-title":"Supportive Care in Cancer"},{"key":"2023010809172777200_bib40","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1002\/cncr.29672","article-title":"Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners","volume":"121","author":"Donovan","year":"2015","journal-title":"Cancer"},{"key":"2023010809172777200_bib41","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1007\/s00520-016-3241-z","article-title":"Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison","volume":"24","author":"Nelson","year":"2016","journal-title":"Supportive Care in Cancer"},{"key":"2023010809172777200_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/cen.14689","article-title":"Effect of estradiol on cognition in men undergoing androgen deprivation therapy: a randomized placebo-controlled trial","author":"Russell","year":"2022","journal-title":"Clinical Endocrinology"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/5\/EJE-22-0318.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/187\/5\/EJE-22-0318.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/5\/617\/48516002\/eje-22-0318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/5\/617\/48516002\/eje-22-0318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:18:08Z","timestamp":1676391488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/5\/617\/6972103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-22-0318","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,9,29]]}}}